2020 Archives - AMSL Diabetes


News and Media

News and Media
2023 2024 2022 2021 2020 2019 2018

Tandem Suspension Notice (Last Updated 1 April 2021)

24th November 2020 Recently the Therapeutic Goods Administration (TGA) expressed concern about the Tandem Diabetes Care t:slim X2 insulin pump. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA to address their concern. However the TGA have informed us of their intent to temporarily suspend the ARTG entry for the t:slim …


Dexcom G4 PLATINUM manufactured by Dexcom – Supply Update

Dexcom G4 PLATINUM manufactured by Dexcom has been discontinued for sales directly from AMSL Diabetes.


t:slim X2 insulin pump with NEW Basal-IQ technology

Basal-IQ technology is now available in Australia!  The t:slim X2 insulin pump with Basal-IQ technology is compatible with the new Dexcom G6 CGM System.


Dexcom G4 PLATINUM & Dexcom G5 Mobile Update

On the 2nd April 2020, Dexcom announced the upcoming obsolescence for Dexcom G4 PLATINUM and Dexcom G5 Mobile at dexcom.com/obsolescence. This specific announcement and timeline is only applicable to residents of the United States.


Important Update: AMSL’s Commitment during COVID-19

Important Message from AMSL General Manager, Ian Slater on COVID-19 23rd March 2020 The impact of COVID-19 has been unprecedented as it continues to affect people and organisations around the world. The Federal Government, State Governments and Health Authorities continue to provide detailed guidelines on how to mitigate risks and ensure containment. We encourage all …


Dexcom G6 CGM System Update

Sydney, Australia, March 2020 The Dexcom G6 Continuous Glucose Monitoring (CGM) System, has been registered in Australia (ARTG 330535).                                                                 Dexcom G6 represents the latest …


The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

Sydney, Australia, March 2020 The Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative from the 1st of March, 2020. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM …


Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Back to top